Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One

View original at finance.yahoo.com
T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One T-Mobile, Metro by T-Mobile and UScellular will offer the new iPhone 17e, which delivers incredible value with faster performance, an advanced camera system, enhanced durability, the magic of MagSafe, and double the starting storag…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • C1X cellular modem offers up to 50 percent faster cellular data performance and up to 30 percent less modem energy usage than iPad Air with M3 for active cellular users

    80% confidence

  • T-Mobile offers the Best Entertainment Bundle in Wireless

    80% confidence

  • C1X modem is up to 2x faster than C1 in iPhone 16e and matches the speed of iPhone Air

    80% confidence

  • T-Mobile has the Best Mobile Network in the U.S. based on analysis of Speedtest Intelligence data from 2H 2025

    80% confidence

  • T-Mobile families have saved over $3,700 versus AT&T and Verizon in the past 5 years based on real monthly bill analysis

    80% confidence

  • Ceramic Shield 2 offers 3x better scratch resistance than the previous generation and reduced glare

    80% confidence

  • iPad Air with M4 is up to 2.3x faster than iPad Air with M1

    80% confidence

  • T-Mobile operates America's Best Network

    80% confidence

  • iPad Air with M4 is up to 30 percent faster than iPad Air with M3

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One — Source | Via News | ViaNews Market